Welcome to the Lymphoma Clinical Roadmap chaired by Dr. Christopher R. Flowers and Dr. Judith Trotman. The Lymphoma Roadmap is a free to access educational curriculum featuring presentations from world leading experts in their field. Every month we will have guest speakers presenting findings on a hot topic and the chairs will join to participate in a debate and question and answers session to dive deep into the subject.
Please register below to get free access to the content and to receive the monthly webinar direct to your email
MD Anderson Cancer Centre, Houston, Texas
Christopher R. Flowers, MD, is Professor and Chair of the Department of Lymphoma and Myeloma at MD Anderson Cancer Center. He has focused on specialized care for patients with lymphoid malignancies. Dr. Flowers graduated from Stanford University from the human biology and humanities honors programs. He remained at Stanford where he completed medical school and received a master’s degree in medical information sciences. After medical school, he completed an internal medicine residency at the University of Washington. He continued his research training in Seattle through the Robert Wood Johnson Clinical Scholars Program and oncology fellowship at the Fred Hutchinson Cancer Research Center.
Christopher R. Flowers, MD, is Professor and Chair of the Department of Lymphoma and Myeloma at MD Anderson Cancer Center. He has focused on specialized care for patients with lymphoid malignancies.
Concord Hospital, Sydney
Professor Judith Trotman, MBChB, FRACP, FRCPA, Spec Cert in Clinical Research (Oncology), is Head of the Hematology Department, Concord Repatriation General Hospital, University of Sydney, AU. An active clinician researcher she has particular expertise in the management of lymphoid malignancies. Professor Trotman is a lymphoma clinician researcher who provides global leadership in charting the role of PET scanning in lymphoma. She is committed to embedding quality clinical trials into clinical care and to the implementation of research findings into practice as evidenced by her successful MBS listing of PET for indolent lymphomas. She has developed a number of digital research initiatives in collaborations with patients, including ClinTrial Refer and the WhiMSICAL study.
Professor Judith Trotman is Head of the Hematology Department, Concord Repatriation General Hospital, University of Sydney, AU. An active clinician researcher she has particular expertise in the management of lymphoid malignancies.
MD Anderson Cancer Center, Texas
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Lymphoma Outcomes Database, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Section Chief, New Drug Development, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
MD Anderson Cancer Center, Texas
Clinical Management and Advances in Chimeric Antigen Receptor T-cell (CAR T) therapy for lymphomas
Hôpital Saint-Louis, Paris
Professor of Haematology in the Paris University, chair of the Lymphoma group at Hospital Saint-Louis, and head of the hemato-oncology department-Paris, France
Prof Thieblemont ‘s major interest is the biological and clinical features of lymphomas. She is involved in clinical trials for the treatment of lymphoma patients, particularly integrating innovative treatments, such cell immunotherapies and CAR T-cells.
Hôpital Saint-Louis, Paris
Updates in Marginal Zone Lymphoma
Stanford University School of Medicine
Ranjana H. Advani, MD is the Saul Rosenberg Professor of Lymphoma and serves as the Physician Leader of the Lymphoma Clinical Care Program. She specializes in research and treatment of Hodgkin and non-Hodgkin lymphomas and has developed a broad collaborative investigative program, encompassing clinical trials and translational correlates. She is the Principle Investigator on numerous clinical trials. She currently serves on the National Comprehensive Cancer Network (NCCN) non Hodgkin and Hodgkin Lymphoma (vice chair) guidelines panel, Lymphoma Core Committee of the Eastern Cooperative Oncology Group (ECOG) and the National Cancer Institute Lymphoma Steering Committee.
Stanford University School of Medicine
Risk Stratification and Therapeutic Approach for First line Hodgkin Lymphoma
Washington University School of Medicine
Dr. Kahl is an associate professor of medicine at the University of Wisconsin School of Medicine and Public Health. He is the director of the UW Lymphoma Service and clinical research director for hematologic malignancies at the Paul P. Carbone Comprehensive Cancer Center. He received his medical degree from Tufts University where he was elected AOA. He completed all post-graduate training at the University of Wisconsin and was appointed to the faculty in 2000.
Washington University School of Medicine
Recent advances in lymphoma clinical trials
Winship Cancer Institute
Pamela Blair Allen, MD, MSc, is Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Allen specializes in the treatment of hematological malignancies and treats patients at Winship Cancer Institute of Emory University (Clifton campus). She is an attending physician in the Bone Marrow and Stem Cell Transplant Center at Winship Cancer Institute. Prior to joining the faculty at Emory in 2017, Dr. Allen was a medical oncology fellow at Northwestern University in Chicago, Illinois.
Winship Cancer Institute
Best practices and Recent Advances in Cutaneous T-cell Lymphoma
MD Anderson Cancer Center, Texas
Dr. Strati received his MD from the University Vita-Salute San Raffaele in Milan, Italy, where he also completed a residency, before an initial fellowship in leukemia at MD Anderson Cancer Center. His initial studies focused on chronic lymphocytic leukemia (CLL). Further studies took him through a fellowship at Queen Mary University in London and a residency at Mayo Clinic, Rochester, before returning to MD Anderson for a clinical fellowship in hematology-oncology, and where he recently accepted a position as Assistant Professor.
MD Anderson Cancer Center, Texas
What’s relevant now in first line follicular lymphoma
University of California Irvine
Professional Positions
Awards and Recognition
Dr. Elizabeth Brém is a triple-board certified UCI Health hematologist-oncologist and medical oncologist who...
University of California Irvine
New Clinical Advances and Research Questions in the Management of Older Patients with Diffuse Large B-cell Lymphoma (DLBCL)
Roswell Park Comprehensive Cancer Center
My name is Dr. Kara Kelly, and I’m a pediatric oncologist and the Chair of Roswell Park Oishei Children’s Cancer and Blood Disorders Program. I specialize in leukemia and lymphoma in children and adolescents, with a specific focus on acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma.
Roswell Park Comprehensive Cancer Center
Caring for Adolescent and Young Adult patients with Lymphoma
Clinical Professor, UWA Medical School, Internal Medicine
Dr Cheah is a Haematologist and Clinical Researcher practising at Hollywood Private and Sir Charles Gairdner Hospitals. He graduated from the University of Western Australia and completed post-graduate training at Fremantle Hospital and Peter MacCallum Cancer Centre (Melbourne). He then completed fellowships in translational research at Peter MacCallum Cancer Centre and an Advanced Fellowship in Lymphoma at the world’s premier cancer institution, MD Anderson Cancer Center (Houston, Texas, USA).
Clinical Professor, UWA Medical School, Internal Medicine
Risk Stratification and Therapeutic Approach for Relapsed Follicular Lymphoma
MD Professor of Clinical Internal Medicine Director of Lymphoma Program The Ohio State University The James Comprehensive Cancer Center Department of Internal Medicine Division of Hematology
Dr. Kami Maddocks is a Professor of Clinical Internal Medicine and Director of the Lymphoma Program in the Division of Hematology. She specializes in treating patients with B-cell lymphomas. Dr. Maddocks conducts research evaluating new-targeted therapies for these lymphomas, with a particular interest in mantle cell lymphoma and diffuse large B cell lymphoma.
The Ohio State University,
The James Comprehensive Cancer Center
Approaches for First Line Management of Diffuse Large B cell Lymphoma (DLBCL)
MD Anderson Cancer Center, Texas
Upon completion of the combined degree program at the University of Pennsylvania, Dr. Chelsea Pinnix embarked on residency training in Radiation Oncology at the University of Texas MD Anderson Cancer Center. Being at MD Anderson was the logical progression in her professional research and clinical development given that it encourages research at the post-doctoral level while offering the insight that can only be gleaned through clinical interactions. Radiation Oncology is an ever-evolving specialty. The unanswered questions continue to compound.
MD Anderson Cancer Center, Texas
What’s New in Radiation Therapy in Lymphoma
MD Anderson Cancer Center, Texas
Dr. Jason Westin is the leader of the diffuse large B-cell lymphoma research team at the University of Texas MD Anderson Cancer Center in the Department of Lymphoma and Myeloma. His research interests include designing and conducting innovative clinical trials, the development of new drugs and new methods to improve outcomes for patients with lymphoma, including the study of scale-free networks and complex systems. Dr. Westin believes that clinical research is our best weapon in the fight against cancer, and has designed and conducted numerous clinical trials to find new cures for cancer.
MD Anderson Cancer Center, Texas
Incorporating new agents into regimens for aggressive B-cell lymphomas
City of Hope, Duarte
Alex Herrera, M.D., earned his undergraduate degree summa cum laude from Princeton University and received his medical degree from Harvard Medical School. Dr. Herrera completed his residency in internal medicine at the Brigham and Women’s Hospital, before pursuing a hematology-oncology fellowship at the Dana-Farber Cancer Institute/Massachusetts General Hospital.
City of Hope, Duarte
Next Steps in Combination Therapies for Relapsed Hodgkin Lymphoma
Charles University Hospital, Prague
Professor Marek Trněný is a Professor of Medical Oncology and Head of the First Faculty of Medicine at Charles University Hospital, Prague, CZ. He graduated from the Faculty of General Medicine at Charles University, Prague, CZ, in 1985, and until 1989 he worked at the Institute of Chemical Technology, Prague, CZ. Since 1990, Prof. Trněný has worked at the General Teaching Hospital and the First Faculty of Medicine and has completed his residency and fellowship in internal medicine, hematology, and medical oncology.
Charles University Hospital, Prague
First line therapy for Mantle Cell Lymphoma
Washington University School of Medicine
Neha Mehta-Shah, MD, MSCI is an Associate Professor of Medicine at Washington University in St. Louis where she specializes in T-cell lymphomas. She completed her undergraduate and medical school at Northwestern University and then completed residency at New York Presbyterian-Weill Cornell Medical Center.
Washington University School of Medicine
Targeted Therapies for T-cell Lymphomas
MD Anderson Cancer Center, Texas
I am a Professor in The Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center. I obtained my M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. I was a Fellow at the Fogarty National Center at NIH and trained in the lab for 6 years on cell biology and molecular biology.
MD Anderson Cancer Center, Texas
Novel approaches for relapsed Mantle Cell Lymphoma
MD Department of Lymphoma - Myeloma, Division of Cancer Medicine
Anderson Cancer Centre
Novel strategies for Enhancing CAR T cell therapy
Olivia Newton-John Cancer Centre, Melbourne
A/Prof Hawkes (MBBS Hons, FRACP, DMedSc) is the Lymphoma Lead at the Olivia Newton-John Cancer Centre, Austin Health and Eastern Health in Melbourne Australia. After completing Medical Oncology training in Melbourne, she undertook a fellowship at the Royal Marsden Hospital, UK and doctoral studies at Melbourne University.
Olivia Newton-John Cancer Centre, Melbourne
Predictive and prognostic biomarkers in lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Improving quality of life and quality of care for patients with lymphoma
Concord Hospital, Sydney
Professor Judith Trotman, MBChB, FRACP, FRCPA, Spec Cert in Clinical Research (Oncology), is Head of the Hematology Department, Concord Repatriation General Hospital, University of Sydney, AU. An active clinician researcher she has particular expertise in the management of lymphoid malignancies. Professor Trotman is a lymphoma clinician researcher who provides global leadership in charting the role of PET scanning in lymphoma. She is committed to embedding quality clinical trials into clinical care and to the implementation of research findings into practice as evidenced by her successful MBS listing of PET for indolent lymphomas. She has developed a number of digital research initiatives in collaborations with patients, including ClinTrial Refer and the WhiMSICAL study.
Concord Hospital, Sydney
Approaches to Imaging in Aggressive Lymphomas
Robert H. Lurie Comprehensive Cancer Center of Northwestern
The Herbert Irving Comprehensive Cancer Center, Columbia University, New York.
Advances in T-cell lymphomas
Barts Cancer Institute, London
I graduated in medicine from the University of Cambridge and subsequently undertook my medical and specialty registrar haematology training in London. My research interests in lymphoma biology was developed during my Kay Kendall funded Clinical Research Fellowship with Professor Jude Fitzgibbon at the Barts Cancer Institute where I investigated the genetic heterogeneity and tumour evolution underlying follicular lymphoma and its progression. I was awarded the Royal College of Pathologists Specialty Research Medal for this work.
Barts Cancer Institute, London
Translating discoveries in follicular lymphoma into practice
Weill Cornell Medicine
Dr. Rutherford is Assistant Professor at Weill Cornell Medicine. Her Lymphoma Clinical Research Mentoring Program (LCRMP) project seeks to use imaging to tailor treatment plans for diffuse large B-cell lymphoma (DLBCL) patients. Most DLBCL patients with advanced stage disease receive a combination therapy called R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone], given in six cycles every three weeks.
Weill Cornell Medicine
Diagnostic and Management Approaches for High-Risk Aggressive B-cell Lymphomas
The University of British Columbia
Dr Laurie Sehn is currently Clinical Professor with the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada. She has been a medical oncologist and clinical investigator at BC Cancer since 1998, and is currently the Chair of the Lymphoma Tumour Group. Dr Sehn graduated from McGill Medical School, Montreal, Canada and received her training in Internal Medicine at Columbia Presbyterian Medical Center, Columbia University, New York, USA.
The University of British Columbia
What’s new for relapsed lymphoma
MD Anderson Cancer Centre, Houston, Texas
Christopher R. Flowers, MD, is Professor and Chair of the Department of Lymphoma and Myeloma at MD Anderson Cancer Center. He has focused on specialized care for patients with lymphoid malignancies. Dr. Flowers graduated from Stanford University from the human biology and humanities honors programs. He remained at Stanford where he completed medical school and received a master’s degree in medical information sciences. After medical school, he completed an internal medicine residency at the University of Washington. He continued his research training in Seattle through the Robert Wood Johnson Clinical Scholars Program and oncology fellowship at the Fred Hutchinson Cancer Research Center.
Concord Hospital, Sydney
Professor Judith Trotman, MBChB, FRACP, FRCPA, Spec Cert in Clinical Research (Oncology), is Head of the Hematology Department, Concord Repatriation General Hospital, University of Sydney, AU. An active clinician researcher she has particular expertise in the management of lymphoid malignancies. Professor Trotman is a lymphoma clinician researcher who provides global leadership in charting the role of PET scanning in lymphoma. She is committed to embedding quality clinical trials into clinical care and to the implementation of research findings into practice as evidenced by her successful MBS listing of PET for indolent lymphomas. She has developed a number of digital research initiatives in collaborations with patients, including ClinTrial Refer and the WhiMSICAL study.
MD Department of Lymphoma - Myeloma, Division of Cancer Medicine
MD Anderson Cancer Center, Texas
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Lymphoma Outcomes Database, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Section Chief, New Drug Development, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
The University of British Columbia
Dr Laurie Sehn is currently Clinical Professor with the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada. She has been a medical oncologist and clinical investigator at BC Cancer since 1998, and is currently the Chair of the Lymphoma Tumour Group. Dr Sehn graduated from McGill Medical School, Montreal, Canada and received her training in Internal Medicine at Columbia Presbyterian Medical Center, Columbia University, New York, USA.
Release date: January 2022 | Expiration date: December 2023
Estimated time to complete activity: up to a maximum of 12 Hours.
If required, please contact MER on: +1 800-421-3756
This activity is jointly provided by Medical Education Resources and MD Education Ltd.
Link to MER Privacy Policy
UK OFFICEMD – Education
4/4a Bloomsbury Square, London
United Kingdom
WC1A 2RP
US OFFICEMD Education USA, LLC
4600 140th Avenue North
Suite 180
Clearwater, FL 33762